TFII.TO -1.7C -0.17MU -19.63CRWD 5.69PANW 4.39SNOW 16.89V 3.35MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.21
+0.20 (0.78%)
as of Aug 3, 2026, 1:30:21 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Oct 23, 2007
Has taken it's licks. If they prevail on their lawsuits on their patents then they will go up. He likes the generics more then the big R & D houses.
Photo of David BaskinDavid BaskinUnlock Rating
$23.98

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 16, 2007
Trading at a very attractive multiple (less then 10X next years earnings), 4.5% dividends. They have a lot of things going on in the pipeline. Must be patient with this though.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$24.63

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 10, 2007
His model price is $42.32 a positive 66% differential. Until they read off their goodwill, the stock will probably be in the doghouse for a while.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.54

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 11, 2007
This is a value stock. A number of its drugs have either come off patent or will be in the next 2, 3 years. On the other hand, it has a strong research/development pipeline and about $19 billion in cash. Cash will be used to raise the dividends, buy back
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.19

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 10, 2007
Many pharmaceuticals are faced with an uncertain political environment. This is more important than patent expirations. They are faced with a national health system in the US if there is a change in the government in 2008.
Photo of Alan Kral , CFA, CICAlan Kral , CFA, CIC
No
Unlock Rating
$23.96

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 29, 2007
You are getting almost 5% yield while waiting for their pipeline to improve. All the bad news about drugs coming off of patent is out now. Have a huge cash horde that they will use at the right time to acquire companies with promising drugs.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.67

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2007
His model price is $39.86, a 61% positive differential. In his top 10. The one consolation on this is that you get a 5% dividend while you wait. Hopes they will write off a lot of their Pharmacia acquisition. Until they do, he doesn't expect much movement.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$24.65

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 16, 2007
Almost 5% yield. Their cholesterol drug is coming off patent, which almost made up 25% of their revenues. They have to find a way to replace this.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$23.39

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 15, 2007
Corrected partly because of the market and also its latest earnings report was somewhat disappointing even though the company advised that the full year and next year's earnings are expected to be as they previously stated. Almost 5% yield, which totally limits downside risk in the stock. On a market turn around, this will be a major participant.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.53

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jul 27, 2007
(A Top Pick July 21/06 Up 1%.) Pays a 5% dividend. His model price is $41.35, a 71% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.79

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 24, 2007
Has been a very frustrating stock to have. Doesn't seem to be able to get out of its own way.
Photo of Brendan CaldwellBrendan Caldwell
Owned
Unlock Rating
$24.89

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 18, 2007
Just reported numbers that were a little bit lighter than expectations. They also reaffirmed their view for next year that they expect to make back the shortfall later in the year. This knee-jerk reaction is an opportunity. 4.5% new.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$25.13

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 17, 2007
Doesn't like the business models of pharmaceutical companies. Can be hit by generics, lawsuits, etc.. Prefers business models with downside protection. After the next US election, expect there will be severe regulations on pharmaceutical prices.
Photo of Pat NaccaratoPat Naccarato
No
Unlock Rating
$25.96

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 17, 2007
A pure pharmaceutical play and he cautious on this sector. Concerned about lawsuits, patent litigations on generic drugs and also patent expiries.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$25.96

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 21, 2007
The model price is $42, a 63% positive differential. All the drug companies are moving, except this one. Huge cash flows. 5% dividend yield.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.92

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
Showing 556 to 570 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG -2.68$146.01
SLB -1.22$48.37
SHEL -0.8$91.18
AAPL -2.76$306.15
AMZN 12.495$284.075
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TFII.TO -1.7$13.38
C -0.17$132.28
MU -19.63$803.4
CRWD 5.69$196.55
PANW 4.39$336.22

Popular Articles

Latest Sell Signals

AAPL -2.76$306.15
AAPL -2.76$306.15
AAPL -2.76$306.15
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like